Elevance Health
845 hedge funds and large institutions have $43.2B invested in Elevance Health in 2017 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 270 increasing their positions, 355 reducing their positions, and 63 closing their positions.
5% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 63
1% less funds holding
Funds holding: 852 → 845 (-7)
1% less capital invested
Capital invested by funds: $43.9B → $43.2B (-$642M)
1.35% less ownership
Funds ownership: 88.03% → 86.69% (-1.3%)
24% less repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 355
33% less funds holding in top 10
Funds holding in top 10: 43 → 29 (-14)
48% less call options, than puts
Call options by funds: $168M | Put options by funds: $326M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$172M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$143M |
| 3 |
N
Natixis
Paris,
France
|
+$126M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$112M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$102M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
-$774M |
| 2 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$256M |
| 3 |
VVP
Vulcan Value Partners
Birmingham,
Alabama
|
-$156M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$110M |
| 5 |
AIM
Assured Investment Management
New York
|
-$99.4M |
ELV Hedge Fund Activity: Q3 2017 in Review
845 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Elevance Health (ELV) for Q3 2017, worth a combined $43.2B — down 1.5% from $43.9B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new ELV positions and 63 closed out — a net gain of 3 holders — while 270 added to existing stakes and 355 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $172M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, cutting an estimated $774M.
- 845 institutional investors held Elevance Health (ELV) as of Q3 2017, down from 852 in Q2 2017.
- Funds reported $43.2B of Elevance Health stock for Q3 2017, down 1.5% quarter-over-quarter.
- 66 funds opened new Elevance Health positions in Q3 2017 and 63 closed out, a net change of +3 holders.
- The largest Elevance Health buyer in Q3 2017 was T. Rowe Price Associates, an estimated $172M added.
- The largest Elevance Health seller in Q3 2017 was Barrow, Hanley, Mewhinney & Strauss, an estimated $774M sold.
Based on aggregated 13F filings for Q3 2017.